Pramipexole dihydrochloride extended-release 0.375mg, 0.75mg, 1.5mg, 2.25mg, 3mg, 3.75mg, 4.5mg; tabs. Swallow whole. May take with food. Initially 0.375mg once daily ...
February 23, 2010 — The US Food and Drug Administration (FDA) has approved a new once-daily formulation of pramipexole dihydrochloride (Mirapex ER tablets, Boehringer Ingelheim Pharmaceuticals, Inc) ...
An experimental drug that combines fixed doses of extended-release (ER) formulations of existing medications can significantly reduce symptoms in patients with untreated early-stage Parkinson's ...
Recently, researchers set out to investigate whether the dopamine receptor agonist pramipexole was safe and effective in treating fibromyalgia. Normally used to treat Parkinson's disease, this drug ...
Sub-group analyses of patients with early Parkinson's disease (PD) at different age groups or baseline disease severities who were treated with P2B001 showed consistently greater symptomatic control ...
Please provide your email address to receive an email when new articles are posted on . P2B001, a pramipexole/rasagiline combination, was similarly efficacious to ...
Patients with restless legs syndrome (RLS) treated with pregabalin (Lyrica) had as much symptom improvement as those receiving pramipexole (Mirapex) in a large year-long trial, with fewer showing ...
Introduction:Pramipexole is a new dopaminergic drug which has been approved for PD treatment. However, we tried to find a new capacity for this drug rather than symptomatic effect. A chronic rotenone ...
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today highlighted the publication in Nature Medicine of PRIME-PRAXOL, an independent, randomized, double-blind, placebo-controlled trial of the dopamine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results